Cboe - Market News Story
Agile Therapeutics Will Present Combined Safety Data From 3 Phase 3 Studies At ACOG Meeting

Benzinga Newsdesk 5/3/2019 7:07:53 AM

Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the combined safety data from three Phase 3 studies of Twirla® (AG200-15), an investigational, once weekly, low-dose hormonal contraceptive patch, will be presented in an interactive ePoster session at the 2019 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists (ACOG) being held May 3rd - 6th, 2019 in Nashville, Tennessee. The poster, titled 'Safety of AG200-15, an Investigational Transdermal Patch, in Three Phase 3 Studies,' will be presented by lead author Anita Nelson, M.D. Dr. Nelson, Professor and Chair of Obstetrics and Gynecology, Western University of Health Sciences, served as Principle Investigator for SECURE, the pivotal Phase 3 study of Twirla (AG200-15).

The presentation details are as follows:

Poster Title: Safety of AG200-15, an Investigational Transdermal Patch, in Three Phase 3 Studies
Poster ID: 1J
Poster Session: ePoster Session J
Date: Saturday May 4, 2019
Time: 11:30 am - 12:30 pm CT

The presentation will report combined safety data in over 3,400 women, including treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), from three Phase 3 studies: the SECURE study (ATI-CL23), single-arm, 13-cycle, open-label, conducted in 2014-2016; and ATI-CL12 and ATI-CL13, which were open-label, randomized, active-controlled (an approved oral contraceptive) trials, conducted in 2010-2011.



Attachments

  • Original document
  • Permalink

Disclaimer

CBOE Holdings Inc. published this content on 03 May 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 03 May 2019 13:07:03 UTC